159 related articles for article (PubMed ID: 21969317)
1. Reversal of new oral anticoagulants.
Battinelli EM
Circulation; 2011 Oct; 124(14):1508-10. PubMed ID: 21969317
[No Abstract] [Full Text] [Related]
2. Letter by Marlu et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects".
Marlu R; Hodaj E; Pernod G
Circulation; 2012 Apr; 125(16):e615; author reply e616. PubMed ID: 22529073
[No Abstract] [Full Text] [Related]
3. Letter by Bernstein et al regarding article, "reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Bernstein RA; Alberts MJ; Garcia DA
Circulation; 2012 Apr; 125(16):e614; author reply e616. PubMed ID: 22529072
[No Abstract] [Full Text] [Related]
4. Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects.
Eerenberg ES; Kamphuisen PW; Sijpkens MK; Meijers JC; Buller HR; Levi M
Circulation; 2011 Oct; 124(14):1573-9. PubMed ID: 21900088
[TBL] [Abstract][Full Text] [Related]
5. Lack of an antagonist to reverse the action of dabigatran.
Jolobe OM
QJM; 2012 Feb; 105(2):212-4. PubMed ID: 22052956
[No Abstract] [Full Text] [Related]
6. Emergency surgery and trauma in patients treated with the new oral anticoagulants: dabigatran, rivaroxaban, and apixaban.
Moorman ML; Nash JE; Stabi KL
J Trauma Acute Care Surg; 2014 Sep; 77(3):486-94; quiz 486-94. PubMed ID: 25159255
[No Abstract] [Full Text] [Related]
7. Pharmacologic interventions for reversing the effects of oral anticoagulants.
Kalus JS
Am J Health Syst Pharm; 2013 May; 70(10 Suppl 1):S12-21. PubMed ID: 23640528
[TBL] [Abstract][Full Text] [Related]
8. Managing new oral anticoagulants in the intensive care unit.
Gass JA; Weeks PA
Crit Care Nurs Q; 2013; 36(4):390-9. PubMed ID: 24002428
[TBL] [Abstract][Full Text] [Related]
9. [Bleeding and surgery in the treatment with new oral anticoagulants. The management can be complicated by the lack of specific antidotes].
Dalén M; Hjemdahl P; Holmström M; Ivert T
Lakartidningen; 2014 Jun 11-17; 111(24):1064-8. PubMed ID: 25129916
[No Abstract] [Full Text] [Related]
10. Laboratory testing for the new oral anticoagulants: a review of current practice.
Favaloro EJ; Bonar R; Butler J; Marsden K
Pathology; 2013 Jun; 45(4):435-7. PubMed ID: 23635821
[No Abstract] [Full Text] [Related]
11. Bleeding and the new anticoagulants: strategies and concerns.
Samama CM; Levy JH
Anesthesiology; 2015 Feb; 122(2):236-7. PubMed ID: 25437499
[No Abstract] [Full Text] [Related]
12. Reverse engineering for new oral anticoagulants: non-specific reversal agents and the anticoagulant activity of dabigatran and rivaroxaban.
Levi M
Thromb Haemost; 2012 Aug; 108(2):201-2. PubMed ID: 22739774
[No Abstract] [Full Text] [Related]
13. Effects on routine coagulation screens and assessment of anticoagulant intensity in patients taking oral dabigatran or rivaroxaban: guidance from the British Committee for Standards in Haematology.
Baglin T; Keeling D; Kitchen S;
Br J Haematol; 2012 Nov; 159(4):427-9. PubMed ID: 22970737
[No Abstract] [Full Text] [Related]
14. Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers.
Marlu R; Hodaj E; Paris A; Albaladejo P; Cracowski JL; Pernod G
Thromb Haemost; 2012 Aug; 108(2):217-24. PubMed ID: 22627883
[TBL] [Abstract][Full Text] [Related]
15. Influence of dabigatran and rivaroxaban on routine coagulation assays. A nationwide Belgian survey.
Van Blerk M; Bailleul E; Chatelain B; Demulder A; Devreese K; Douxfils J; Jochmans K; Mullier F; Wijns W; Soumali MR; Coucke W; Vernelen K; Van de Walle P
Thromb Haemost; 2015 Jan; 113(1):154-64. PubMed ID: 25231101
[TBL] [Abstract][Full Text] [Related]
16. Favorable outcome after a subdural hematoma treated with feiba in a 77-year-old patient treated by rivaroxaban.
Maurice-Szamburski A; Graillon T; Bruder N
J Neurosurg Anesthesiol; 2014 Apr; 26(2):183. PubMed ID: 24296541
[No Abstract] [Full Text] [Related]
17. Thrombin generation using the calibrated automated thrombinoscope to assess reversibility of dabigatran and rivaroxaban.
Herrmann R; Thom J; Wood A; Phillips M; Muhammad S; Baker R
Thromb Haemost; 2014 May; 111(5):989-95. PubMed ID: 24352511
[TBL] [Abstract][Full Text] [Related]
18. Bleeding and antidotes in new oral anticoagulants.
Majeed A; Schulman S
Best Pract Res Clin Haematol; 2013 Jun; 26(2):191-202. PubMed ID: 23953907
[TBL] [Abstract][Full Text] [Related]
19. Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model.
Grottke O; van Ryn J; Spronk HM; Rossaint R
Crit Care; 2014 Feb; 18(1):R27. PubMed ID: 24499559
[TBL] [Abstract][Full Text] [Related]
20. Reversal of rivaroxaban-induced anticoagulation with prothrombin complex concentrate, activated prothrombin complex concentrate and recombinant activated factor VII in vitro.
Perzborn E; Heitmeier S; Laux V; Buchmüller A
Thromb Res; 2014 Apr; 133(4):671-81. PubMed ID: 24529498
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
